Condition: Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or Cancer · Sponsor: Astellas Pharma Global Development, Inc.
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive). Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. Certain stomach and GEJ cancers may be treated with immunotherapy, which helps the body's immune system fight cancer. This study will give more information about how well zolbetuximab works when given with an immunotherapy medicine called pembrolizumab and chemotherapy. In this study, adults with stomach cancer or GEJ cancer will either be given zolbetuximab with pembrolizumab and chemotherapy or a placebo with pembrolizumab and chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. The main aim of the study is to check how long people with stomach cancer and GEJ cancer live after treatment with zolbetuximab with pembrolizumab and chemotherapy compared to placebo with pembrolizumab and chemotherapy. Adults with locally advanced unresectable or metastatic stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearb…
This description comes directly from the study's public registry record.
Astellas Pharma Global Development Inc. · 800-888-7704 · astellas.registration@astellas.com
Always discuss trial participation with your own doctor first.
| UAB Medicine - UAB Hospital | Birmingham, Alabama, United States | Recruiting |
| CBCC Global Research - Comprehensive Blood & Cancer Center | Bakersfield, California, United States | Recruiting |
| TOI Clinical Research | Cerritos, California, United States | Recruiting |
| University of California, San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| The Angeles Clinic and Research Institute, West Los Angeles Office | Los Angeles, California, United States | Recruiting |
| Hartford HealthCare - Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Recruiting |
| MedStar Georgetown University Hospital / Lombardi Comprehensive Cancer Center | Washington D.C., District of Columbia, United States | Recruiting |
| Piedmont Physician Medical Oncology Atlanta | Atlanta, Georgia, United States | Recruiting |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Recruiting |
| Franciscan Health Oncology and Hematology Specialists | Indianapolis, Indiana, United States | Recruiting |
| Holden Comprehensive Cancer Center | Iowa City, Iowa, United States | Recruiting |
+ 237 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06901531